Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 202

1.

Toll-like receptors in inflammation, infection and cancer.

Chen K, Huang J, Gong W, Iribarren P, Dunlop NM, Wang JM.

Int Immunopharmacol. 2007 Oct;7(10):1271-85. Epub 2007 Jun 21. Review.

PMID:
17673142
2.

Toll-like receptors: function and roles in lung disease.

Basu S, Fenton MJ.

Am J Physiol Lung Cell Mol Physiol. 2004 May;286(5):L887-92. Review.

PMID:
15064235
3.

Toll-like receptors: emerging concepts in kidney disease.

Anders HJ, Schlöndorff D.

Curr Opin Nephrol Hypertens. 2007 May;16(3):177-83. Review.

PMID:
17420659
4.
5.

Toll-like receptors, inflammation and cancer.

Tsan MF.

Semin Cancer Biol. 2006 Feb;16(1):32-7. Epub 2005 Sep 8. Review.

PMID:
16153858
6.

Toll-like receptors in inflammation of the central nervous system.

Kong Y, Le Y.

Int Immunopharmacol. 2011 Oct;11(10):1407-14. doi: 10.1016/j.intimp.2011.04.025. Epub 2011 May 18. Review.

PMID:
21600311
7.

Therapeutic targeting of toll-like receptors in gastrointestinal inflammation.

Ishihara S, Rumi MA, Ortega-Cava CF, Kazumori H, Kadowaki Y, Ishimura N, Kinoshita Y.

Curr Pharm Des. 2006;12(32):4215-28. Review.

PMID:
17100624
8.

Toll-Like receptors (TLRs) and their ligands.

Uematsu S, Akira S.

Handb Exp Pharmacol. 2008;(183):1-20. Review.

PMID:
18071652
9.

Toll-like receptors as targets for inflammation, development and repair in the central nervous system.

van Noort JM.

Curr Opin Investig Drugs. 2007 Jan;8(1):60-5. Review.

PMID:
17263186
10.

RAGE and TLRs: relatives, friends or neighbours?

Ibrahim ZA, Armour CL, Phipps S, Sukkar MB.

Mol Immunol. 2013 Dec;56(4):739-44. doi: 10.1016/j.molimm.2013.07.008. Epub 2013 Aug 14. Review.

PMID:
23954397
11.

The significance of toll-like receptors in human diseases.

Montero Vega MT, de Andrés Martín A.

Allergol Immunopathol (Madr). 2009 Sep-Oct;37(5):252-63. doi: 10.1016/j.aller.2009.04.004. Epub 2009 Oct 22. Review.

PMID:
19853360
12.

Viral recognition by Toll-like receptors.

Barton GM.

Semin Immunol. 2007 Feb;19(1):33-40. Epub 2007 Mar 2. Review.

PMID:
17336545
13.

Activation of the innate immune system in atherosclerotic disease.

Oude Nijhuis MM, van Keulen JK, Pasterkamp G, Quax PH, de Kleijn DP.

Curr Pharm Des. 2007;13(10):983-94. Review.

PMID:
17430162
14.

Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists.

Kanzler H, Barrat FJ, Hessel EM, Coffman RL.

Nat Med. 2007 May;13(5):552-9. Review.

PMID:
17479101
15.

Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders.

Fukata M, Vamadevan AS, Abreu MT.

Semin Immunol. 2009 Aug;21(4):242-53. doi: 10.1016/j.smim.2009.06.005. Review.

PMID:
19748439
16.
17.

Endogenous inflammatory molecules engage Toll-like receptors in cardiovascular disease.

Ionita MG, Arslan F, de Kleijn DP, Pasterkamp G.

J Innate Immun. 2010;2(4):307-15. doi: 10.1159/000314270. Epub 2010 Apr 30. Review.

18.

Toll-like receptors and immune regulation: implications for cancer therapy.

Wang RF, Miyahara Y, Wang HY.

Oncogene. 2008 Jan 7;27(2):181-9. doi: 10.1038/sj.onc.1210906. Review.

PMID:
18176599
19.

The toll of Toll-like receptors, especially toll-like receptor 2, on murine atherosclerosis.

Curtiss LK, Tobias PS.

Curr Drug Targets. 2007 Dec;8(12):1230-8. Review.

PMID:
18220700
20.

What is the role of Toll-like receptors in bacterial infections?

Gerold G, Zychlinsky A, de Diego JL.

Semin Immunol. 2007 Feb;19(1):41-7. Epub 2007 Feb 5. Review.

PMID:
17280841

Supplemental Content

Support Center